MIT and Recursion Unveil AI Model Boltz-2 for Accelerated Drug Discovery

Edited by: Veronika Radoslavskaya

Cambridge, MA - The Massachusetts Institute of Technology (MIT) and biotechnology company Recursion have launched Boltz-2, an advanced AI model.

Boltz-2 predicts protein structures and drug-binding strengths, crucial for drug effectiveness. This model builds upon its predecessor, Boltz-1, and offers unprecedented speed and accuracy.

The model is open-source, allowing global researchers access. The collaboration between MIT and Recursion combines academic expertise with advanced computational resources. Boltz-2 is expected to accelerate drug development and improve patient outcomes.

Sources

  • Zawya.com

  • Recursion Pharmaceuticals, Inc. - MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

  • Boltz-2: democratising the future of drug design | Cancer Grand Challenges

  • MIT and Recursion Release Boltz-2, an AI Breakthrough in Drug Discovery Modeling

Read more news on this topic:

Microsoft Launches Mu: On-Device AI Model for Copilot+ PCs

AI Generates Levels for Video Games, Saving Development Time

AI Outperforms Humans in Emotional Intelligence Assessments, Study Finds

Did you find an error or inaccuracy?

We will consider your comments as soon as possible.